Peripheral blood leukocyte telomere length as a possible prognostic marker for the development of atrial fibrillation

Cover Page

Abstract


Atrial fibrillation is one of the most common heart rhythm disorders. The most prominent risk factor for atrial fibrillation is advanced age. Population ageing contributes to an increase in both the prevalence of this pathology and socio-economic burden of the disease for society in general and the patient in particular. Adequate therapy and prevention of atrial fibrillation requires the search for novel prognostic risk markers for disease development, progression, and patients’ response to therapy. One of these markers is the length of telomeres – structures at the ends of chromosomes that protect them from degradation during cell division. The article provides an overview of world studies, both confirming and disproving the role of leukocyte telomere length in atrial fibrillation development.


Full Text

Restricted Access

About the authors

Svetlana Yu. Nikulina

Voino-Yasenetsky Krasnoyarsk State Medical University

Author for correspondence.
Email: nicoulina@mail.ru

Russian Federation, Krasnoyarsk

D. Sci. (Med.), Prof., Voino-Yasenetsky Krasnoyarsk State Medical University

Ksenya Yu. Shihkova

Voino-Yasenetsky Krasnoyarsk State Medical University

Email: tadtaeva93@mail.ru

Russian Federation, Krasnoyarsk

Graduate Student, Voino-Yasenetsky Krasnoyarsk State Medical University

Vladimir A. Shulman

Voino-Yasenetsky Krasnoyarsk State Medical University

Email: shulman36@mail.ru

Russian Federation, Krasnoyarsk

Prof., Voino-Yasenetsky Krasnoyarsk State Medical University

Anna A. Chernova

Voino-Yasenetsky Krasnoyarsk State Medical University

Email: anechkachernova@yandex.ru

Russian Federation, Krasnoyarsk

D. Sci. (Med.), Prof., Voino-Yasenetsky Krasnoyarsk State Medical University

Vladimir N. Maksimov

Institute of Internal and Preventive Medicine – a branch of the Federal Research Center Institute of Cytology and Genetics

Email: medik11@mail.ru

Russian Federation, Novosibirsk

D. Sci. (Med.), Prof., Institute of Internal and Preventive Medicine – a branch of the Federal Research Center Institute of Cytology and Genetics

References

  1. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Rev Esp Cardiol (Engl Ed) 2017; 70 (1): 50. doi: 10.1016/j.rec.2016.11.033
  2. Camm A, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369–429. doi: 10.1093/eurheartj/ehq278
  3. Calado R, Young N. Telomeres in disease. F1000 Med Rep 2012; 4: 8. doi: 10.3410/M4-8
  4. Von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005; 5 (2): 197–203. doi: 10.2174/1566524053586545
  5. Benetos A, Kark JD, Susser E et al. Tracking and fixed ranking of leukocyte telomere length across the adult life course. Aging Cell 2013; 12 (4): 615–21. doi: 10.1111/acel.12086
  6. Bendix L, Thinggaard M, Fenger M et al. Longitudinal changes in leukocyte telomere length and mortality in humans. J Gerontol A Biol Sci Med Sci 2014; 69 (2): 231–9. DOI: 10.1093/ gerona/glt153
  7. Maximov VN, Malyutina SK, Orlov PS et al. Leukocyte Telomere Length as an Aging Marker and Risk Factor for Human Age-Related Diseases. Adv Gerontol 2017; 7 (2): 101–6. doi: 10.1134/S2079057017020102
  8. Roberts JD, Dewland TA, Longoria J et al. Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. Circ Arrhythm Electrophysiol 2014; 7 (6): 1026–32. doi: 10.1161/CIRCEP.114.001781
  9. Staerk L, Wang B, Lunetta KL et al. Association Between Leukocyte Telomere Length and the Risk of Incident Atrial Fibrillation: The Framingham Heart Study. J Am Heart Assoc 2017; 6 (11): e006541. doi: 10.1161/JAHA.117.006541
  10. Siland JE, Geelhoed B, van Gelder IC et al. Telomere length and incident atrial fibrillation – data of the PREVEND cohort. PLoS One 2017; 12 (2): e0171545. doi: 10.1371/journal.pone. 0171545
  11. Carlquist JF, Knight S, Cawthon RM et al. Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. Heart Rhythm 2016; 13 (1): 21–7. doi: 10.1016/j.hrthm.2015.07.032
  12. Correction in the Article by Kirchhof et al. «2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS». Rev Esp Cardiol 2017; 70: 50.e1–e84. Rev Esp Cardiol (Engl Ed) 2017; 70 (11): 1031. doi: 10.1016/j.rec.2017.07.009
  13. Zhang N, Fan C, Gong M et al. Leucocyte telomere length and paroxysmal atrial fibrillation: A prospective cohort study and systematic review with meta-analysis. J Clin Lab Anal 2018; 32 (9): e22599. doi: 10.1002/jcla.22599
  14. Kaufman ES. Recurrent atrial fibrillation after ablation: Can telomere length identify patients who are young at heart? J Cardiovasc Electrophysiol 2019; 30 (7): 1125–6. doi: 10.1111/jce.13960
  15. Su C, Liu Z, Gao Y et al. Study on the relationship between telomere length changes and recurrence of atrial fibrillation after radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2019; 30 (7): 1117–24. doi: 10.1111/jce.13958
  16. Pan KL, Hsiao YW, Lin YJ et al. Shorter Leukocyte Telomere Length Is Associated With Atrial Remodeling and Predicts Recurrence in Younger Patients With Paroxysmal Atrial Fibrillation After Radiofrequency Ablation. Circ J 2019; 83 (7): 1449–55. doi: 10.1253/circj.CJ-18-0880
  17. Allende M, Molina E, Gonzalez-Porras JR et al. Short Leukocyte Telomere Length Is Associated With Cardioembolic Stroke Risk in Patients With Atrial Fibrillation. Stroke 2016; 47 (3): 863–5. doi: 10.1161/STROKEAHA.115.011837

Statistics

Views

Abstract - 2

PDF (Russian) - 0

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies